BioSpace News Archive

Clovis Oncology, Inc. announced that three posters highlighting studies from the Rubraca® clinical development program will be presented at the ESMO Congress 2019, September 27 – October 1, 2019, in Barcelona, Spain.

Tocagen Inc. announced that the Toca 5 Phase 3, randomized, multi-center clinical trial evaluating Toca 511 & Toca FC in patients with recurrent high grade glioma undergoing resection missed the primary endpoint of overall survival compared to standard of care treatment.

East Lancashire Hospitals NHS Trust, a large integrated healthcare organization serving over a half million patients in north west England, has joined the TriNetX global health research network to improve its research intelligence capabilities, bring more research opportunities to its patients, and enhance overall study performance for sponsors.

Shaklee Corporation was honored to feature Wayne Westcott, Ph.D. as a keynote speaker at the Science Symposium held as part of its 2019 Global Conference in July.

I-Mab Biopharma announced the appointment of Mr. Neil K. Warma as General Manager of I-Mab Biopharma U.S., Limited on September 3rd.

Late-Breaking Results Include First Durability Data from Phase 1b Study of KSI-301 in Treatment-Naïve Patients with Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion [12-September-2019] PALO ALTO, Calif. , Sept. 12, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel therapeut

Moderna, Inc. announced positive data from the three-month interim analysis of safety and immunogenicity of the Phase 1 study of its investigational cytomegalovirus vaccine.

Moderna, Inc. announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults.

Data will be shared with health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Genentech, a member of the Roche Group, presented full pivotal Phase III study results for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder, a rare, debilitating central nervous system disease.